Navidea Biopharmaceuticals to Announce First Quarter 2016 Financial Results on May 17, 2016
May 10 2016 - 4:30PM
Business Wire
- Conference call with investment community
to follow at 8:00 a.m. ET -
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today
announced that the Company will report its financial results for
the first quarter 2016, on Tuesday, May 17, 2016 prior to a
conference call with the investment community scheduled at 8:00
a.m. ET.
Investors and the public are invited to access the live audio
webcast through the link below. Participants are encouraged to
log-in and/or dial-in fifteen minutes before the conference call
begins. The webcast replay is expected to be available on our
investor website, http://ir.navidea.com, approximately two to four
hours after the live event.
Event: Navidea Biopharmaceuticals Q1 2016 Financial Results
Conference Call Date/Time: Tuesday, May 17, 2016 at 8:00 a.m. ET
Webcast Link:
http://edge.media-server.com/m/p/b5ki35y5/lan/en
Dial-in Number – US: 1 (855) 897-5884 Dial in Number – Int’l: 1
(720) 634-2940 Participant Passcode:
11165733
Replay
A webcast replay will be available on the
Investor Relations section of our website at http://ir.navidea.com
for 30 days.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision immunodiagnostic agents and
immunotherapeutics. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. The
development activities of the Manocept immunotherapeutic platform
will be conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics. Navidea’s strategy is to deliver superior
growth and shareholder return by bringing to market novel products
and advancing the Company’s pipeline through global partnering and
commercialization efforts. For more information, please visit
www.navidea.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160510006891/en/
Navidea BiopharmaceuticalsInvestors &
MediaSharon Correia, 978-655-2686Senior Director, Corporate
Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024